Editas Medicine, Inc.·4

Jun 4, 6:37 PM ET

Burkly Linda 4

4 · Editas Medicine, Inc. · Filed Jun 4, 2025

Insider Transaction Report

Form 4
Period: 2025-06-03
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Transactions
  • Sale

    Common Stock

    2025-06-03$1.72/sh726$1,25269,519 total
Footnotes (2)
  • [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.
  • [F2]This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7522. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file
  • 4
    wk-form4_1749076666.xmlPrimary

    FORM 4